Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Icahn School of Medicine at Mount Sinai · King's College London · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
292
total citations
- FWCI
- 49.40
- Percentile
- 100%
- References
- 32
Citations per year
Authors
143- BEBruce E. SandsCorresponding
Icahn School of Medicine at Mount Sinai
- PMPeter M. Irving
King's College London, Guy's and St Thomas' NHS Foundation Trust
- THTimothy Hoops
Johnson & Johnson (United States), Janssen (United States)
- JIJames Izanec
Janssen (United States), Janssen Scientific Affairs (United States)
- LGLong-Long Gao
Janssen (United States), Janssen Scientific Affairs (United States)
Topics & keywords
Topics
Keywords
- Medicine
- Ustekinumab
- Adalimumab
- Clinical endpoint
- Crohn's disease
- Internal medicine
- Clinical trial
- Population
No related works found for this paper.